Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India

Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta‐analysis

“…Han et al reported that rs6277 C>T (CC vs TT) was correlated with a lower improvement to risperidone ( P < 0.001). In the study by Kaur et al, significant differences in the frequencies of TaqID (rs1800498) were found among the responder, partial responder, and nonresponder groups ( P = 0.01). No significant association was found between rs1076562 and the response to risperidone treatment by Xing et al …”

“…Subsequently, another 304 studies were excluded after an initial review of the titles and abstracts. The full text of the remaining 85 included articles was retrieved, which encompassed 12 studies that satisfied the inclusion criteria (Figure ) . A manual search of the reference lists contained within these studies did not yield any new eligible studies.…”

“…Within the DRD2 genotype, there were nine SNPs polymorphisms of interest. In the meta‐analysis of the relationship of Taq1A (rs1800497) to risperidone treatment response, 552 patients were included in three studies . There was no significant difference between each genotype in response to risperidone (A1A1 vs A1A2: OR: 1.03, 95% CI: 0.56‐1.90, P = 0.91; A1A1 vs A2A2: OR: 1.17, 95% CI: 0.64‐2.13, P = 0.61; A1A2 vs A2A2: OR: 1.14, 95% CI: 0.79‐1.65, P = 0.48; Figure ).…”

“…In the meta‐analysis of Taq1B (rs17294542), the studies of Xing et al and Kaur et al were included (456 patients in total). The polymorphism of TaqIB is not likely to be associated with the response to risperidone treatment (B1B1 vs B1B2: OR: 1.89, 95% CI: 0.93‐3.85, P = 0.08; B1B1 vs B2B2: OR: 2.01, 95% CI: 0.97‐4.13, P = 0.06; B1B2 vs B2B2: OR: 1.07, 95% CI: 0.72‐1.59, P = 0.74; Figure ).…”

“…The association between dopamine receptor genes and the effect of risperidone treatment has been explored in several studies [7][8][9][10][11][12][13][14][15][16][17][18] ; however, a consistent association between the efficacy of risperidone and genetic factors has not been established. In the present study, we therefore summarized the current pharmacogenetic literature to evaluate the correlation between dopamine receptor genes and the response to risperidone in patients with schizophrenia and performed a meta-analysis of available studies.…”